Antifungal Agents — MCQs
Which of the following antifungal agents is used in combination therapy for cryptococcal meningitis?
Which of the following is not a part of P. versicolor treatment -
Amphotericin B acts on:-
Which drug should not be given with ketoconazole?
Which of the following statements about Ciclesonide is incorrect?
All of the following drugs cause renal failure except?
What is the primary advantage of the newer liposomal preparation of amphotericin B?
Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
Emtricitabine is a/an:
Griseofulvin is not useful in one of the following
Antifungal Agents Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following antifungal agents is used in combination therapy for cryptococcal meningitis?
- A. Flucytosine (Correct Answer)
- B. Nystatin
- C. Terbinafine
- D. Voriconazole
Explanation: **Flucytosine** - **Flucytosine** is commonly used in combination with **amphotericin B** for the initial treatment of **cryptococcal meningitis** [1][2][3]. - This combination therapy allows for synergy, improving efficacy and potentially reducing the dosage and toxicity of amphotericin B [1]. *Nystatin* - **Nystatin** is an antifungal agent primarily used for topical or oral treatment of **mucocutaneous candidiasis**. - It is not systemically absorbed and therefore ineffective for invasive infections like **cryptococcal meningitis**. *Terbinafine* - **Terbinafine** is an antifungal drug mainly used to treat **dermatophyte infections**, such as athlete's foot and onychomycosis [2]. - Its mechanism of action targets fungal ergosterol synthesis at an early stage, which is not suitable for treating **cryptococcal meningitis**. *Voriconazole* - **Voriconazole** is a broad-spectrum azole antifungal used for severe invasive fungal infections, including **aspergillosis** and **candidiasis** [2]. - While it has some activity against *Cryptococcus*, it is not the preferred or standard agent for initial combination therapy for **cryptococcal meningitis**, for which amphotericin B and flucytosine are typically used [2].
Question 2: Which of the following is not a part of P. versicolor treatment -
- A. Selenium sulfide
- B. Clotrimazole
- C. Ketoconazole
- D. Griseofulvin (Correct Answer)
Explanation: **Griseofulvin (Correct - NOT used for P. versicolor)** - **Griseofulvin** interferes with fungal cell division and is primarily used for dermatophyte infections of the skin, hair, and nails, not superficial yeast infections like *P. versicolor*. - It is systemically absorbed and incorporated into **keratin precursor cells**, offering protection against dermatophytes in newly formed tissue. - *Malassezia* species (causing P. versicolor) are **yeasts**, not dermatophytes, making griseofulvin ineffective. *Selenium sulfide (Incorrect - IS used)* - **Selenium sulfide** is an effective topical antifungal agent commonly used in shampoos and lotions to treat *P. versicolor* by inhibiting the growth of *Malassezia* species. - It works by reducing **sebum production** and having a direct fungistatic effect on the yeast. *Clotrimazole (Incorrect - IS used)* - **Clotrimazole** is a broad-spectrum azole antifungal that is very effective as a topical treatment for *P. versicolor* by inhibiting ergosterol synthesis in the fungal cell membrane. - It works well for localized patches of the infection. *Ketoconazole (Incorrect - IS used)* - **Ketoconazole**, another azole antifungal, is highly effective for *P. versicolor* and can be used topically (shampoos, creams) or orally in more extensive or recalcitrant cases. - It disrupts the fungal cell membrane by inhibiting the synthesis of **ergosterol**.
Question 3: Amphotericin B acts on:-
- A. Cell membrane (Correct Answer)
- B. Cytoplasm
- C. Nucleus
- D. Cell wall
Explanation: ***Cell membrane*** Amphotericin B primarily targets the **ergosterol** in the fungal **cell membrane** [1]. It binds to **ergosterol**, forming pores and disrupting the membrane's integrity, leading to leakage of cellular contents and ultimately cell death [1]. *Cytoplasm* The cytoplasm is the internal fluid of the cell where many metabolic processes occur, but it is **not the primary target** of amphotericin B's fungicidal action. While cytoplasmic contents leak out due to membrane damage, the drug does not directly act on cytoplasmic components to exert its effect. *Nucleus* The nucleus contains the genetic material of the fungal cell, but amphotericin B does **not directly interact with nuclear components** or DNA. Damage to the cell membrane is the primary mechanism, with nuclear function only indirectly affected by overall cellular disruption. *Cell wall* Fungal cell walls are composed of **chitin and glucans**, but amphotericin B **does not target these components**. Its action is distinct from drugs that inhibit cell wall synthesis, such as echinocandins.
Question 4: Which drug should not be given with ketoconazole?
- A. Indinavir (Correct Answer)
- B. Macrolide
- C. All of the options
- D. Aminoglycoside
Explanation: ***Correct: Indinavir*** - **Indinavir** is a **protease inhibitor (antiretroviral)** that is primarily metabolized by **CYP3A4** - **Ketoconazole** is a **potent CYP3A4 inhibitor** that significantly increases indinavir plasma concentrations - Co-administration leads to **increased risk of indinavir toxicity** including nephrolithiasis, hyperbilirubinemia, and hepatotoxicity - **Dose reduction of indinavir is required** if concurrent use is necessary (typically reduce to 600 mg q8h from 800 mg q8h) *Incorrect: Macrolide* - Many **macrolides** (erythromycin, clarithromycin) are CYP3A4 substrates and can interact with ketoconazole - While caution is advised due to **QT prolongation risk**, this interaction is less severe than with indinavir - Not an absolute contraindication but requires monitoring *Incorrect: Aminoglycoside* - **Aminoglycosides** (gentamicin, amikacin, tobramycin) are **NOT metabolized by CYP450 enzymes** - They are **hydrophilic** and eliminated **unchanged by renal excretion** - **No clinically significant interaction** with ketoconazole - Can be safely co-administered without dose adjustment *Key Learning Point* - Ketoconazole inhibits CYP3A4, affecting metabolism of many drugs including **protease inhibitors, calcium channel blockers, statins, and some macrolides** - Always check for CYP3A4 substrate drugs when prescribing azole antifungals
Question 5: Which of the following statements about Ciclesonide is incorrect?
- A. Oral candidiasis is common with its use. (Correct Answer)
- B. It is a prodrug activated by bronchial esterase.
- C. It has comparable efficacy to other inhalational corticosteroids.
- D. It has fewer side effects than other inhalational corticosteroids.
- E. It has low systemic bioavailability due to extensive first-pass metabolism.
Explanation: ***Oral candidiasis is common with its use.*** * Ciclesonide is a **prodrug** that is activated in the lungs, which minimizes systemic exposure and reduces the risk of local side effects like **oral candidiasis**. * Therefore, oral candidiasis is **less common** with ciclesonide compared to other inhaled corticosteroids that deliver the active drug directly to the oral cavity. *It is a prodrug activated by bronchial esterase.* * Ciclesonide is indeed a **prodrug** that is converted into its active metabolite, **des-ciclesonide**, by **esterases** primarily found in the lungs. * This specific activation mechanism helps ensure that the drug's therapeutic effects are localized to the airways while minimizing systemic exposure. *It has comparable efficacy to other inhalational corticosteroids.* * Studies have shown that ciclesonide provides **comparable efficacy** to other established inhaled corticosteroids in controlling asthma symptoms and improving lung function. * Its potent anti-inflammatory effects are effective in reducing airway hyperresponsiveness and inflammation. *It has fewer side effects than other inhalational corticosteroids.* * Because ciclesonide is a prodrug activated in the lungs and has a **high protein binding capacity**, it has a reduced likelihood of systemic side effects. * This contributes to a **favorable safety profile**, with a lower incidence of both local and systemic adverse drug reactions compared to some other inhaled corticosteroids. *It has low systemic bioavailability due to extensive first-pass metabolism.* * Ciclesonide has **very low systemic bioavailability** (<1%) when administered via inhalation. * The active metabolite des-ciclesonide that does reach systemic circulation undergoes **extensive first-pass metabolism** in the liver, further reducing systemic exposure. * This pharmacokinetic property contributes to its excellent safety profile and minimal systemic adverse effects.
Question 6: All of the following drugs cause renal failure except?
- A. Cefoperazone (Correct Answer)
- B. Amphotericin B
- C. Gentamicin
- D. Cephaloridine
Explanation: ***Cefoperazone*** - **Cefoperazone** is a third-generation cephalosporin that is primarily eliminated by the liver and does not typically cause **nephrotoxicity**. - While all cephalosporins can potentially cause hypersensitivity reactions or interstitial nephritis in rare cases, cefoperazone is not known for direct renal tubular damage. *Amphotericin B* - **Amphotericin B** is a potent antifungal agent that frequently causes dose-dependent **nephrotoxicity** due to direct damage to renal tubular cells. - It can lead to acute kidney injury, electrolyte imbalances (e.g., **hypokalemia**, **hypomagnesemia**), and renal tubular acidosis. *Gentamicin* - **Gentamicin** is an aminoglycoside antibiotic known for its significant **nephrotoxic** potential, particularly with prolonged use or high doses. - It accumulates in renal cortical cells, leading to **proximal tubular necrosis** and acute tubular necrosis. *Cephaloridine* - **Cephaloridine** is a first-generation cephalosporin that was historically removed from the market due to its significant and dose-dependent **nephrotoxicity**. - It caused direct damage to the **renal tubules**, leading to acute kidney injury.
Question 7: What is the primary advantage of the newer liposomal preparation of amphotericin B?
- A. Lower tissue uptake in the kidneys.
- B. Reduced nephrotoxicity. (Correct Answer)
- C. Similar efficacy and antifungal spectrum as conventional preparations.
- D. All of the above
Explanation: ***Reduced nephrotoxicity*** - The liposomal formulation encapsulates **amphotericin B**, reducing its direct interaction with renal tubular cells. - This encapsulation minimizes the drug's impact on kidney function, which is a major dose-limiting toxicity of conventional amphotericin B. *Similar efficacy and antifungal spectrum as conventional preparations* - While maintaining efficacy is a goal, the primary advantage of liposomal amphotericin B is its **improved safety profile**, specifically reduced toxicity. - The efficacy and spectrum are generally comparable to the conventional form, but this is not the main reason for its development or preference. *Lower tissue uptake in the kidneys* - This statement is partially true in that the liposomal formulation is designed to **reduce drug accumulation specifically in the kidneys**, which contributes to lower nephrotoxicity. - However, the most direct and crucial advantage is the resulting *reduction in nephrotoxicity* itself, rather than just the mechanism of lower uptake. *All of the above* - This option is incorrect because while liposomal amphotericin B does have similar efficacy and reduced kidney uptake, the overarching primary advantage that makes it clinically superior is the **significantly reduced nephrotoxicity**.
Question 8: Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
- A. Amiodarone + Atorvastatin
- B. Carbamazepine + Atorvastatin
- C. Atorvastatin + Itraconazole (Correct Answer)
- D. Phenytoin + Atorvastatin
Explanation: ***Atorvastatin + Itraconazole*** - **Itraconazole** is a potent inhibitor of **CYP3A4**, the primary enzyme responsible for atorvastatin's metabolism. - Co-administration leads to significantly increased **atorvastatin plasma concentrations**, raising the risk of severe side effects like **rhabdomyolysis** and **hepatotoxicity**. *Amiodarone + Atorvastatin* - **Amiodarone** is a moderate **CYP3A4 inhibitor** and can increase atorvastatin levels, but the inhibition is **less potent** than itraconazole. - While this combination does carry a risk and requires dose adjustment, the interaction is **less severe** compared to the potent inhibition seen with itraconazole. - The direct CYP inhibition leading to severe atorvastatin toxicity is less pronounced than with itraconazole. *Carbamazepine + Atorvastatin* - **Carbamazepine** is a potent **CYP3A4 inducer**, meaning it would increase the metabolism of atorvastatin, potentially *decreasing* its efficacy rather than causing toxicity through inhibition. - This interaction would typically lead to subtherapeutic atorvastatin levels, rather than severe toxicity. *Phenytoin + Atorvastatin* - **Phenytoin** is also a potent **CYP3A4 inducer**, similar to carbamazepine. - Concurrent use would likely lead to enhanced metabolism and **reduced efficacy of atorvastatin**, not increased toxicity due to enzyme inhibition.
Question 9: Emtricitabine is a/an:
- A. Alkylating agent
- B. Mitotic inhibitor
- C. Nucleoside reverse transcriptase inhibitor (NRTI) (Correct Answer)
- D. None of the options
Explanation: ***Nucleoside reverse transcriptase inhibitor (NRTI)*** - **Emtricitabine** is a synthetic nucleoside analog that inhibits the activity of HIV-1 **reverse transcriptase**, an enzyme essential for viral replication. - It works by being phosphorylated to its active triphosphate form, which then competes with natural deoxycytidine triphosphate for incorporation into the viral DNA, leading to **chain termination**. *Alkylating agent* - **Alkylating agents** are a class of antineoplastic drugs that work by adding an alkyl group to DNA, forming a covalent bond that interferes with DNA replication and transcription. - They are primarily used in **cancer chemotherapy**, not as antiviral agents for HIV. *Mitotic inhibitor* - **Mitotic inhibitors** are drugs that interfere with cell division (mitosis) by targeting microtubules, either inhibiting their polymerization or depolymerization. - These agents are also used in **cancer treatment** to prevent rapidly dividing cells from completing mitosis. *None of the options* - This option is incorrect because **emtricitabine** clearly belongs to the class of **nucleoside reverse transcriptase inhibitors**.
Question 10: Griseofulvin is not useful in one of the following
- A. Tinea capitis
- B. Tinea pedis
- C. Tinea versicolor (Correct Answer)
- D. Tinea cruris
Explanation: ***Tinea versicolor*** - **Griseofulvin** acts by interfering with **microtubule function** and fungal cell division, making it effective against dermatophytes. - **Tinea versicolor** is caused by *Malassezia* species, which are yeasts and not dermatophytes, rendering griseofulvin ineffective. *Tinea capitis* - This **dermatophyte infection** of the scalp responds well to griseofulvin, which accumulates in keratin-rich tissues. - The medication's ability to reach the **hair shaft** is crucial for treating this condition. *Tinea pedis* - Also known as **athlete's foot**, this is a common **dermatophyte infection** of the feet effectively treated by griseofulvin. - Griseofulvin's deposition into the **stratum corneum** and other keratinized structures helps eliminate the fungus. *Tinea Cruris* - This **dermatophyte infection** of the groin ("jock itch") is sensitive to griseofulvin. - Griseofulvin inhibits **fungal growth** by disrupting mitotic spindle formation in dermatophytes.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free